New real-world analysis reports lower risk of major bleeding with dabigatran compared to rivaroxaban in stroke prevention
A large observational study by researchers from the U.S. FDA has found that dabigatran (150 mg twice daily) was associated with lower rates of intracranial haemorrhage and major extracranial bleeding, including major gastrointestinal bleeding than rivaroxaban (20 mg once daily) in patients with atrial fibrillation (AF). The study is the largest observational study to-date comparing the two drugs, and analysed data from over 118,000 AF patients. Based on the data published in JAMA Internal Medicine, the accompanying Editor’s Note written by Parks and Redberg suggests that physicians should “prescribe dabigatran over rivaroxaban for patients with atrial fibrillation.”
New highly specialised heart procedure at Mater Dei
Times of Malta, 27 March 2016
Four patients got the benefit of an “atrial fibrillation ablation”. They would normally have been sent to centres in London or Oxford, Robert Xuereb, Mater Dei Hospital’s cardiology chairman, told The Sunday Times of Malta.
In Pursuit of Excellence in the Prevention of AF-Related Stroke
AF Association, January 2016
In January 2016, AF Association release the In Pursuit of Excellence in the Prevention of AF-Related Stroke Report. The report captures insights and discussion from a multi-stakeholder group, generated as part of a roundtable meeting and through follow-up with experts, to assess the current situation for the management of AF patients in England, including challenges to optimal care, best practice examples and practical solutions.
To view and download the report click here.
Leading cardiologists unveil ‘Indian Consensus Guidance on Stroke Prevention in Atrial Fibrillation’
Pharmabiz, 10 February 2016
For the first time in the country, 14 leading cardiologists from across the country have launched 'Indian consensus guidance on stroke prevention in atrial fibrillation' to help doctors with diagnosis and management procedures to prevent stroke in patients with atrial fibrillation (AF).
Vorhofflimmern früher erkennen – Schlaganfälle besser verhindern
Kompetenznetz Vorhofflimmern, 23 November 2015
Alle zehn Minuten ereignet sich in Deutschland ein Schlaganfall, der durch die Herzrhythmusstörung Vorhofflimmern verursacht ist.
New FDA approved smartphone device to monitor heart's health, test-marketed in Madison
WKOW, 23 October 2015
A new FDA approved gadget is being test marketed right here in Madison area Walgreens. The goal is to provide peace of mind to heart patients worried about their heart's rhythm.
FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa
FDA, 16 October 2015
The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.
At Chicagoland, NBA legend Jerry West discusses battle with AFib
Fox Sports, 19 September 2015
Friday at Chicagoland Speedway, 14-time NBA All-Star Jerry West, one of the true legends of the game, was at the track to talk about AFib Awareness Month.
Billie Jean King talks AFib and stroke risk
Fox News, 13 September 2015
Billie Jean King teamed up with Janssen Pharmaceuticals, Inc. to raise awareness about the risk of stroke for those who have atrial fibrillation (AFib).
SmartHealthToday: September is AFIB (Atrial Fibrillation Awareness) Month; what it is, what to do
Northern Kentucky Tribune, 5 September 2015
September is Atrial Fibrillation Awareness Month and we’ll be sharing a related story each week throughout the month. First up is explaining what atrial fibrillation (or AFib) is.